Denali Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de Denali Therapeutics es Ryan Watts , nombrado en Aug 2015, tiene una permanencia de 9.25 años. compensación anual total es $7.88M, compuesta por 8.5% salario y 91.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.57% de las acciones de la empresa, por valor de €61.34M. La antigüedad media del equipo directivo y de la junta directiva es de 5.8 años y 8.1 años, respectivamente.

Información clave

Ryan Watts

Chief Executive Officer (CEO)

US$7.9m

Compensación total

Porcentaje del salario del CEO	8.5%
Permanencia del CEO	9.3yrs
Participación del CEO	1.6%
Permanencia media de la dirección	5.8yrs
Promedio de permanencia en la Junta Directiva	8.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ryan Watts en comparación con los beneficios de Denali Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$427m
Jun 30 2024	n/a	n/a	-US$420m
Mar 31 2024	n/a	n/a	-US$137m
Dec 31 2023	US$8m	US$670k	-US$145m
Sep 30 2023	n/a	n/a	-US$124m
Jun 30 2023	n/a	n/a	-US$128m
Mar 31 2023	n/a	n/a	-US$371m
Dec 31 2022	US$9m	US$645k	-US$326m
Sep 30 2022	n/a	n/a	-US$303m
Jun 30 2022	n/a	n/a	-US$284m
Mar 31 2022	n/a	n/a	-US$286m
Dec 31 2021	US$13m	US$610k	-US$291m
Sep 30 2021	n/a	n/a	US$30m
Jun 30 2021	n/a	n/a	US$56m
Mar 31 2021	n/a	n/a	US$58m
Dec 31 2020	US$9m	US$589k	US$71m
Sep 30 2020	n/a	n/a	-US$228m
Jun 30 2020	n/a	n/a	-US$216m
Mar 31 2020	n/a	n/a	-US$215m
Dec 31 2019	US$5m	US$567k	-US$198m
Sep 30 2019	n/a	n/a	-US$66m
Jun 30 2019	n/a	n/a	-US$55m
Mar 31 2019	n/a	n/a	-US$52m
Dec 31 2018	US$6m	US$545k	-US$36m
Sep 30 2018	n/a	n/a	-US$137m
Jun 30 2018	n/a	n/a	-US$123m
Mar 31 2018	n/a	n/a	-US$91m
Dec 31 2017	US$1m	US$481k	-US$88m

Compensación vs. Mercado: La compensación total de Ryan($USD7.88M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD2.14M).

Compensación vs. Ingresos: La compensación de Ryan ha sido consistente con los resultados de la empresa en el último año.

CEO

Ryan Watts (48 yo)

9.3yrs

Permanencia

US$7,879,267

Compensación

Dr. Ryan J. Watts, Ph D., serves as Director at PEEL Therapeutics, Inc. since February 2023. He is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since Au...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ryan Watts	Co-Founder	9.3yrs	US$7.88m	1.57% € 61.3m
Alexander Schuth	Co-Founder	9.7yrs	US$4.17m	0.41% € 16.0m
Marc Tessier-Lavigne	Co-Founder & Independent Director	no data	US$431.93k	1.47% € 57.8m
Carole Ho	Chief Medical Officer & Head of Development	9.4yrs	US$4.17m	0.15% € 5.7m
Tyler Nielsen	Senior Vice President of Corporate Finance	no data	sin datos	sin datos
Dana Andersen	Chief Technical and Manufacturing Officer	6.3yrs	sin datos	sin datos
Joe Lewcock	Chief Scientific Officer	4.3yrs	sin datos	sin datos
Laura Hansen	Vice President of Investor Relations	4.8yrs	sin datos	sin datos
Chris Walsh	General Counsel	5.8yrs	sin datos	sin datos
Mark Rowen	Vice President of Corporate Development	1.8yrs	sin datos	sin datos
Cindy Dunkle	Chief People Officer	no data	sin datos	sin datos
Katie Peng	Chief Commercial Officer	3.2yrs	sin datos	sin datos

5.8yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 4DN es experimentado (5.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ryan Watts	Co-Founder	9.7yrs	US$7.88m	1.57% € 61.3m
Marc Tessier-Lavigne	Co-Founder & Independent Director	9.7yrs	US$431.93k	1.47% € 57.8m
Vicki Sato	Independent Chairperson	9.6yrs	US$459.43k	0.076% € 3.0m
Jay Flatley	Independent Director	9.6yrs	US$444.43k	0.24% € 9.3m
Eric Reiman	Member of Scientific Advisory Board	no data	sin datos	sin datos
David Schenkein	Independent Director	9.6yrs	US$439.43k	0.051% € 2.0m
David Holtzman	Member of Scientific Advisory Board	4yrs	sin datos	sin datos
Peter Klein	Independent Director	6.7yrs	US$439.43k	0.011% € 425.1k
Jennifer Cook	Independent Director	6yrs	US$429.43k	0.0098% € 385.2k
Steve Krognes	Director	2.5yrs	US$419.43k	0.58% € 22.6m
Scott Biller	Member of Scientific Advisory Board	no data	sin datos	sin datos
Stacie Weninger	Member of Scientific Advisory Board	3.8yrs	sin datos	sin datos

8.1yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de 4DN se considera experimentada (8.1 años de antigüedad promedio).

Denali Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Denali Therapeutics Inc., Annual General Meeting, May 31, 2024

Insufficient new directors

Co-Founder recently sold €310k worth of stock

Co-Founder recently sold €98k worth of stock

Co-Founder recently sold €136k worth of stock

Insider recently sold €85k worth of stock

Recent updates

New major risk - Revenue size

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

First half 2024 earnings released: US$1.27 loss per share (vs US$0.53 profit in 1H 2023)

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial

Denali Therapeutics Inc., Annual General Meeting, May 31, 2024

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP

Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP

New major risk - Revenue and earnings growth

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium

Denali Therapeutics Inc. Announces Presentations on Its Investigational Blood-Brain Barrier (Bbb)-Crossing Enzyme Replacement Therapies At the Upcoming 2024 Worldsymposium

Insufficient new directors

Co-Founder recently sold €310k worth of stock

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Third quarter 2023 earnings released: US$0.72 loss per share (vs US$0.84 loss in 3Q 2022)

New minor risk - Share price stability

Denali Therapeutics Inc. Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: US$1.34 (vs US$0.48 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.80 loss per share (vs US$0.53 loss in 1Q 2022)

Full year 2022 earnings released: US$2.60 loss per share (vs US$2.39 loss in FY 2021)

Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle Development Programs for MPS Diseases at the Upcoming WORLDSymposium™

Co-Founder recently sold €98k worth of stock

Co-Founder recently sold €136k worth of stock

Denali Therapeutics Announces DNL343 Interim Phase 1B Data in ALS and Entry into the Healey ALS Platform Trial

Third quarter 2022 earnings released: US$0.84 loss per share (vs US$0.69 loss in 3Q 2021)

Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with Tak-594/Dnl593 (Ptv:Pgrn) and Progression to Enrolling Participants with Ftd-Grn

Biogen Inc. and Denali Therapeutics Announce Initiation of the Phase 3 Lighthouse Study in Parkinson's Disease Associated with Lrrk2 Pathogenic Mutations

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome)

Insider recently sold €85k worth of stock

Second quarter 2022 earnings released: US$0.48 loss per share (vs US$0.50 loss in 2Q 2021)

Co-Founder recently sold €697k worth of stock

Denali Therapeutics and Biogen Announce Initiation of Phase 2B Study of Lrrk2 Inhibitor in Parkinson's Disease

First quarter 2022 earnings released: US$0.53 loss per share (vs US$0.58 loss in 1Q 2021)

Denali Therapeutics Inc. Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi

Denali Therapeutics Inc., Annual General Meeting, Jun 02, 2022

Co-Founder recently sold €615k worth of stock

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Co-Founder recently sold €89k worth of stock

Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial

Denali Therapeutics Announces Appointment of Erik Harris to Board of Directors

Denali Therapeutics Inc. Announces U.S. Food and Drug Administration Clinical Hold on DNL919 Investigational New Drug (IND) Application

Co-Founder recently sold €2.5m worth of stock

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.54 loss in 3Q 2020)

Co-Founder recently sold €435k worth of stock

Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS

Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN

Insider recently sold €108k worth of stock

Second quarter 2021 earnings released: US$0.50 loss per share (vs US$0.56 loss in 2Q 2020)

Director Jay Flatley sitting on 4 company boards

Director Jay Flatley sitting on 4 company boards

First quarter 2021 earnings released: US$0.58 loss per share (vs US$0.55 loss in 1Q 2020)

Denali Therapeutics Inc. Announces Final Results from Phase 1 and Phase 1B Studies of Its Small Molecule LRRK2 Inhibitor, BIIB122/DNL151

Denali Therapeutics Inc. Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)

New 90-day low: €50.16

Co-Founder recently sold €549k worth of stock

Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)

Denali Therapeutics Inc. Appoints Nancy Thornberry to the Board of Directors

Denali Therapeutics Inc. Enters into A Settlement Agreement with A Stockholders to Resolve Lawsuit

Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors

Independent Director recently sold €368k worth of stock

New 90-day high: €60.82

Denali Therapeutics Announces First Human Biomarker Proof of Concept for its Transport Vehicle (TV) Technology Achieved in Phase 1/2 Study of ETV:IDS (DNL310) in Hunter Syndrome (MPS II)

Revenue misses expectations

Third quarter 2020 earnings released: US$0.54 loss per share

New 90-day high: €38.86